Intensive Insulin Therapy in Type 2 Diabetes (T2D) Patients Previously Treated with Glargine Plus Oral Agents: Prandial NPL/Lispro Mixtures vs Glargine/Lispro Basal/Bolus

Rosenstock, Julio; Ahmann, Andrew J.; Colon, Gildred; Scism-Bacon, Jamie L.; Jiang, Honghua H.; Martin, Sherry
June 2007
Diabetes;Jun2007 Supplement 1, Vol. 56, pA51
Academic Journal
We report the first head-to-head comparison of intensive insulin therapies (intensive mixtures therapy [IMT] vs basal bolus therapy [BBT]) in T2D patients previously treated with glargine (≥30 U/d) + oral agents. Patients with A1C ≥ 7.5 and ≤ 12% were randomized to IMT (lispro mix 50/50; 50% NPL, 50% lispro; n=187) rid with meals or BBT (glargine at bedtime + mealtime lispro; n=187) in a 24-wk, multicenter, open-label, non-inferiority trial using structured insulin titration to achieve fasting/preprandial plasma glucose (PG) <110 mg/dL (<6.1 mM). Patients on IMT not reaching FPG target could switch to lispro mix 75/25 (75% NPL; 25% lispro) at the PM meal. Baseline characteristics were similar (mean): age 55yrs, diabetes duration 11yrs, BMI 34 kg/m² and A1C (IMT 8.8%, BBT 8.9%, P=0.6041). At wk 24, A1C was lower with BBT (6.8 vs 6.9%, P=0.021) and A1C was reduced significantly from baseline for both therapies (P<0.0001). The difference in A1C change from baseline to endpoint (BBT minus IMT) was -0.22% with a 90% CI from -0.38% to -0.06%. Non-inferiority was not demonstrated based on the pre-specified margin of 0.3%. The % of patients on IMT vs BBT achieving target A1C <7.0% was 54% vs 69% (P=0.009) and for target ≤6.5% was 35% vs 50% (P=0.01), but did not differ for target ≤6.0% (14.6% vs 14.3%, P=1.0) or for target <7.5% (81% vs 83%, P=0.76). Treatment with BBT was associated with higher insulin dose (1.38 U/kg vs 1.17 U/kg, P=0.002). Weight gain was similar for both groups (IMT: 3.98 kg vs BBT: 4.55 kg, P=0.22). Rates of overall, nocturnal, severe hypoglycemia, or hypoglycemia confirmed by PG values were also similar. In conclusion, as non-inferiority of IMT to BBT was not demonstrated, findings on A1C reduction, % achieving specific A1C targets, hypoglycemia, insulin dose, and number of injections need to be considered in the individual decision-making process of selecting IMT vs BBT in T2D necessitating intensive insulin therapy.


Related Articles

  • Intensive blood glucose control for type 2 diabetes: meta-analysis.  // Africa Health;Mar2012, Vol. 34 Issue 3, p59 

    The article reports on a meta-analysis of intensive blood glucose control for type 2 diabetes, which found that intensive control could not minimize all-cause mortality, however, can increase the risk of severe hypoglycaemia by about 30%.

  • Adjunctive prandial or biphasic insulin for type 2 diabetes improved glycaemic control but increased hypoglycaemia and weight gain. Hollmand, R. R. // Evidence Based Medicine;Jun2008, Vol. 13 Issue 3, p77 

    STUDY DESIGN Design: randomised controlled trial (Treating to Target in Type 2 Diabetes [4-T]). Allocation: concealed. Blinding: unblinded. STUDY QUESTION Setting: 58 centres in Ireland and the UK. Patients: 708 patients ⩾18 years of age (mean age 62 y, 64% men) who had type 2 diabetes for...

  • Efficacy of once-daily insulin.  // Primary Care Reports;Dec2009 Pharmacology Watch Supp, p1 

    The article discusses a new study on the use of once-a-day insulin to treat type 2 diabetes. The study was conducted by researchers from England, involving 708 patient who had suboptimal hemoglobin A1c. It was found that the basal insulin group presented lesser hypoglycemic episodes as well as...

  • Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes. Riddle, Matthew; Pencek, Richard; Charenkavanich, Supoat; Lutz, Karen; Wilhelm, Ken; Porter, Lisa // Diabetes Care;Sep2009, Vol. 32 Issue 9, p1577 

    OBJECTIVE -- To compare the efficacy and safety of adding mealtime pramlintide or rapid-acting insulin analogs (RAIAs) to basal insulin for patients with inadequately controlled type 2 diabetes. RESEARCH DESIGN AND METHODS -- In a 24-week open-label, multicenter study, 113 patients were randomly...

  • Insulin-Based Versus Triple Oral Therapy for Newly Diagnosed Type 2 Diabetes. Lingvay, Ildiko; Legendre, Jaime L.; Kaloyanova, Polina F.; Zhang, Song; Adams-Huet, Beverley; Raskin, Philip // Diabetes Care;Oct2009, Vol. 32 Issue 10, p1789 

    OBJECTIVE -- Early use of insulin after diagnosis of type 2 diabetes is met with resistance because of associated weight gain, hypoglycemia, and fear of decreased compliance and quality of life (QoL). RESEARCH DESIGN AND METHODS-- In treatment-naive patients with newly diagnosed type 2 diabetes,...

  • Early Insulin Treatment in Type 2 Diabetes. Meneghini, Luigi F. // Diabetes Care;Nov2009 Supplement, Vol. 32, pS266 

    The article focuses on the early introduction of insulin therapy in newly diagnosed patients with type 2 diabetes. The potential physiological effects of insulin replacement treatment is discussed. It notes that aggressive and frequently utilization of insulin treatment at disease onset in type...

  • Adjunctive inhaled insulin before meals improved glycaemic control more than adjunctive metformin in lype 2 diabetes mellitus. Barnett, A. H.; Dreyer, M.; Lange, P.; Kudva, Yogish C.; Basu, Ananda // Evidence Based Medicine;Dec2006, Vol. 11 Issue 6, p176 

    The article cites that adjunctive inhaled insulin before meals improved glycemic control more than adjunctive metformin in type 2 diabetes mellitus. Poor glycemic control may be caused by an unacceptable route of medication and fear of hypoglycemia. Monotherapy choices for the treatment of type...

  • Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine. RIDDLE, MATTHEW C.; FORST, THOMAS; ARONSON, RONNIE; SAUQUE-REYNA, LEOBARDO; SOUHAMI, ELISABETH; SILVESTRE, LOUISE; LIN PING; ROSENSTOCK, JULIO // Diabetes Care;Sep2013, Vol. 36 Issue 9, p2497 

    OBJECTIVE--When oral therapy for type 2 diabetes is ineffective, adding basal insulin improves glycemic control. However, when glycated hemoglobin (HbA1c) remains elevated because of postprandial hyperglycemia, the next therapeutic step is controversial. We examined the efficacy and safety of...

  • RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes (RABBIT 2 Trial). Smiley, Dawn D.; Zisman, Ariel; Prieto, Luz M.; Ceron, Miguel; Palacio, Andres; Puig, Alvaro; Mejia, Roberto; Umpierrez, Guillermo E. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA50 

    The association of inpatient hyperglycemia and poor clinical outcome is well established. Few studies have focused on the optimal management of hyperglycemia in non-ICU patients with type 2 diabetes mellitus (T2DM). Accordingly, we conducted a prospective, randomized multicenter trial to compare...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics